Wekeyar Druggist & Chemist Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 49.30%
(FY 2023)
- Profit 39.74%
(FY 2023)
- Ebitda 138.67%
(FY 2023)
- Net Worth 79.92%
(FY 2023)
- Total Assets -0.53%
(FY 2023)
About Wekeyar Druggist & Chemist
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chita Patra and Jayasen Patra serve as directors at the Company.
- CIN/LLPIN
U51397OR2019PTC031410
- Company No.
031410
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Wekeyar Druggist & Chemist?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chita Patra  | Director | 30-Jul-2019 | Current |
| Jayasen Patra | Director | 30-Jul-2019 | Current |
Financial Performance of Wekeyar Druggist & Chemist.
Wekeyar Druggist & Chemist Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 49.3% increase. The company also saw a substantial improvement in profitability, with a 39.74% increase in profit. The company's net worth Soared by an impressive increase of 79.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wekeyar Druggist & Chemist?
In 2023, Wekeyar Druggist & Chemist had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
P C Patra And Sons Retail Private LimitedActive 11 years 11 monthsChita Patra and Jayasen Patra are mutual person
Wekeyar Industries Private LimitedActive 5 years 7 monthsChita Patra and Jayasen Patra are mutual person
- Wekeyar Plus Pharma Private LimitedActive 5 years 4 months
Chita Patra and Jayasen Patra are mutual person
- Wekeyar International Corporation Private LimitedActive 5 years 2 months
Jayasen Patra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wekeyar Druggist & Chemist?
Unlock and access historical data on people associated with Wekeyar Druggist & Chemist, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wekeyar Druggist & Chemist, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wekeyar Druggist & Chemist's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
